Regeneron Files Antitrust Lawsuit Accusing Amgen Of Engaging In A Persistent Exclusionary Campaign To Deny Patients Access To Praluent® - Antitrust, EU Competition

Late last week, Regeneron Pharmaceuticals, Inc. filed an antitrust complaint against Amgen Inc. in the U.S. District Court for the District of Delaware.

Related Keywords

New York ,United States ,Delaware ,California ,Amgen Enbrel ,Amgen Repatha ,Amgen ,Regeneron Pharmaceuticals Inc ,Amgen Inc ,Us District Court ,Party Payors ,Regeneron Pharmaceuticals ,Third Party Payors ,Sub Market Through Bundling ,Attempted Monopolization ,Sub Market Through Below Cost Pricing ,Unreasonable Restraint ,Exclude Praluent ,Unfair Competition ,Unfair Practices Act ,Cartwright Act ,Donnelly Act ,General Business Law ,Tortious Interference ,Prospective Business ,Mondaq ,Regeneron Files Antitrust Lawsuit Accusing Amgen Of Engaging Ina Persistent Exclusionary Campaign To Deny Patients Access Praluent Xae ,Anti Trust Competition Law ,Antitrust ,U Competition ,Food ,Drugs ,Healthcare ,Life Sciences ,Food And Drugs Law , ,